# To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

> **NCT01755429** · — · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01755429
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2012-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755429, "To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01755429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*